BARD1 and prostate cancer: The implementation of high-throughput genetic diagnostics at an early stage of prostate cancer assessment would not only significantly shorten the overall diagnostic process by identifying potential predictive, prognostic, and targeted therapy factors but also provide valuable information on hereditary predispositions, as demonstrated in our study by the detection of a germline BARD1 pathogenic variant.